
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies Ltd is positioned for growth, driven by positive developments in its photocurable dermal filler and breast-implant programs, potentially enhancing market outlook and cash flow. The company's newly operational U.S.-based logistics center is expected to boost sales for its BioInk and rhCollagen products, particularly as adoption increases among research institutions and tissue-engineering clients. Additionally, the ongoing partnership with AbbVie, which includes exclusive licensing for developing dermal fillers, combined with advancements in CollPlant's product pipeline, underpins a favorable financial trajectory for the company.
Bears say
CollPlant Biotechnologies Ltd has experienced a negative market reaction following a modest capital raise, indicating a loss of investor confidence amid challenging capital market conditions. The pricing at $1.25 per share suggests ongoing pressure on the company's equity and highlights limited options for capital formation. Additionally, the company has adjusted its forecasts by reducing expectations for key products, including Dermal Fillers and BioInk, while also removing Breast Implants from financial models, emphasizing the uncertainty and early-stage developments within its product offerings.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares